Stay up to date with our newsletter

Get in touch!

To explore career opportunities with Sai Life Sciences, share your CV here.

Lets start the conversation!

Sign up to our newsletter

Thank you!
We will be in touch shortly.

2019.06.26

Sai’s new production block

Sai’s new production block now open for business!

The brand-new API and Intermediate manufacturing facility (Block #8) at Sai Life Sciences is the company’s largest block in terms of volume and size. It marks a 70% increase in reactor volume taking the combined capacity past 400 KL.  The project was completed in an accelerated time-frame of 15 months and had the distinction of clocking 0.5 million manhours of project execution without a single lost time incident!

In addition to the increased volumetric capacity, Block #8 provides the flexibility to handle low and high volumes in a single block with 32 reactors (16 production trains) of sizes ranging from 1 KL to 10 KL. It has next generation automation, advanced containment systems, a separate storage area for staging of raw material and intermediates, an increased ratio of filter dryers to reactors ratio, a dedicated vacuum system for every two reactors, and a 5 KL cryo reactor.

Share article

More News

2026.03.10

AI-driven retrosynthesis integrated into Discovery Chemistry

Sai Life Sciences has entered into a collaboration with Chemical.AI, a technology company specialising in computer-aided synthesis design, to integrate an AI-driven retrosynthesis platform into its Discovery Chemistry workflows. The integration enables medicinal chemists to evaluate synthetic routes more rapidly and explore a broader set of feasible pathways during early-stage drug discovery. Retrosynthesis is a […]
Read more

2026.03.10

Structural Biology capabilities launched with X-Ray Crystallography

Sai Life Sciences has introduced integrated structural biology capabilities with the establishment of X-ray protein crystallography workflows to support structure-based drug discovery programs. The platform encompasses end-to-end protein engineering capabilities, including construct design, gene synthesis, and in-house recombinant protein expression and purification. These foundational steps enable generation of high-quality protein material suitable for structural and […]
Read more

2026.03.09

New Medicinal Chemistry block set for inauguration in Hyderabad

A new Medicinal Chemistry block, Unit VIII, is set for inauguration at IKP, Genome Valley, Hyderabad, expanding discovery capacity to meet growing program demand. The four-floor facility spans approximately 100,000 sq. ft. and is designed to support large, multi-disciplinary project teams. It accommodates more than 200 fume hoods and includes a tightly integrated analytical laboratory […]
Read more

2026.03.09

AI-enabled production and material planning platform implemented

Over the past several months, focused AI pilot initiatives have been conducted across operations to evaluate practical applications that strengthen execution. One such initiative is now live across the network: Optimus, an integrated AI-enabled production and material planning platform, implemented at the end of December 2025. Optimus consolidates capacity planning, equipment allocation, and material availability […]
Read more

2026.03.09

Commercial-scale Photo Flow Chemistry successfully executed in Bidar

Commercial-scale flow chemistry has been successfully executed at our API manufacturing site in Bidar for a late-phase program supporting a US-based innovator. This execution builds on prior investments in continuous processing infrastructure at the site, including a 3-litre photo flow reactor equipped with a monochromatic blue LED light source. The platform enables controlled photochemical transformations […]
Read more